05/26/2026
Pharma services remains one of the strongest sectors in healthcare, supported by durable demand, available capital, and resilient valuations. Yet several underappreciated trends are beginning to reshape how value is created and evaluated.
In Skytale’s latest blog, we explore three developments likely to matter most over the next 24 months:
• Why specialization is increasingly outperforming integration
• How CDMO capacity timing may become a critical valuation variable
• Why AI ex*****on alone may not be enough without commercial model evolution
For founders preparing for a process and sponsors building positions in the space, understanding where buyer expectations are shifting may become increasingly important.
Read the full blog: https://hubs.ly/Q04hXV7T0